The biotech firm priced 8.58 million shares at $15.00 each, securing $128.7 million for CRISPR-based therapies.
Scribe Therapeutics completed its initial public offering, selling 8.58 million shares at $15.00 per share, the upper end of its marketed range. The deal raised $128.7 million for the clinical-stage company, which develops in vivo CRISPR technologies aimed at extending healthy lifespan.
The IPO was upsized from initial plans, reflecting strong investor demand. Scribe focuses on engineered CRISPR systems designed for therapeutic applications, competing in a growing biotech sector targeting genetic disorders.
Shares are expected to begin trading on the Nasdaq under the ticker SCTX.